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ABSTRACT
Here, we present an update of Breast Cancer Now
Tissue Bank bioinformatics, a rich platform for the
sharing, mining, integration and analysis of breast
cancer data. Its modalities provide researchers with
access to a centralised information gateway from
which they can access a network of bioinformatic re-
sources to query findings from publicly available, in-
house and experimental data generated using sam-
ples supplied from the Breast Cancer Now Tissue
Bank. This in silico environment aims to help re-
searchers use breast cancer data to their full po-
tential, irrespective of any bioinformatics barriers.
For this new release, a complete overhaul of the IT
and bioinformatic infrastructure underlying the por-
tal has been conducted and a host of novel analytical
modules established. We developed and adopted an
automated data selection and prioritisation system,
expanded the data content and included tissue and
cell line data generated from The Cancer Genome
Atlas and the Cancer Cell Line Encyclopedia, de-
signed a host of novel analytical modalities and en-
hanced the query building process. Furthermore, the
results are presented in an interactive format, provid-
ing researchers with greater control over the infor-
mation on which they want to focus. Breast Cancer
Now Tissue Bank bioinformatics can be accessed at
http://bioinformatics.breastcancertissuebank.org/.
INTRODUCTION
Rapid advances in technology in conjunction with their ap-
plication to national and international cancer projects al-
lows for a formidable amount of biological data to be gen-
erated at an unprecedented rate. As such, the importance of
tissue banking to precision medicine has never been more
relevant to cancer research than it is today. It is vital that
the cancer research community has access to well-annotated
tissues and the tools it requires to analyse data generated
alongside the data that is accumulating in the public do-
main to translate these findings into personalised diagnos-
tic, prognostic and therapeutic strategies.
The Breast Cancer Now Tissue Bank (BCNTB; http:
//breastcancertissuebank.org) was established in 2010 in re-
sponse to a GAP analysis that highlighted a void in high-
quality and fully annotated breast tissues in cancer research
(1). Presented to researchers in the UK and Ireland in 2012,
the BCNTB provides access to over 48,000 samples from
breast tissue and blood/blood derivatives, and offers a be-
spoke cell line service.
Building a biobank is a notable feat but to ensure that
our understanding of breast cancer remains abreast with
advances in technology, we need to unite disparate fields of
research and build a compendium of science from which re-
searchers are able to address all of their needs. The aim is
to create an in silico environment that has a symbiotic rela-
tionship with the in vivo and in vitro components of its tissue
bank.
The BCNTB bioinformatics portal (BCNTBbp) was the
first step in this process (2). This initiative was developed for
the Bank––specifically as a portal from which researchers
could mine and analyse breast cancer data. It provided re-
searchers with the ability to mine literature data and access
basic transcriptomic analyses conducted on publicly avail-
able -omics data. Here we describe the next evolutionary
stage of this in silico resource, in which the BCNTBbp tran-
sitions from a stand-alone repository to an integrated re-
search platform.
Since our last release, the bioinformatic infrastructure of
the portal has been redesigned to accommodate the growth
of data and analytical modalities offered by the Platform,
and lay the foundations for links to specimen information
available from the BCNTB. Other key developments in-
clude implementing novel analytical modalities, capable of
analysing and integrating data generated using a range of
technologies, adopting an automated system for data selec-
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tion and retrieval, and enhancing the data content as well
as the query-building process. Finally, we set the framework
to allow researchers to analyse and integrate findings from
publicly available data, in-house data and experimental data
generated using samples supplied from the biobank. With
the niches of this biobanking ecosystem working together
seamlessly, the patient information available from the BC-
NTB will be updated continuously to include the molecu-
lar data generated by BCNTB bioinformatics. This will in-




Automated data selection, prioritisation and retrieval system.
BCNTB:Analytics has adopted the Smart Automatic Clas-
sification system (SMAC; Pirrò et al., manuscript in prepa-
ration) to select, prioritise and retrieve datasets. Developed
using Ruby, SMAC conducts a text search of titles and
abstracts in PubMed using Boolean logical operators and
retrieves documents as single XML-format files. The arti-
cles extracted are enriched by Medical Subject Headings
(MeSH) terms and ranked according to a weighted score
based on the total number of citations in PubMed, the abun-
dance in breast cancer-related articles and the MeSH tree
hierarchical level. A robust rank aggregation (RRA) algo-
rithm (3), which assumes the null distribution of all the
rank ratios as uniform on the unit interval, is applied to the
ranked articles to ensure that statistically-relevant papers
are prioritised in the analytical workflow. At the most basic
level, these relationships can be viewed as cross-references
between an established controlled vocabulary and the con-
tent of the paper. For each publication that fulfils the crite-
ria, the PubMed identifier (PMID), title, abstract, and iden-
tifiers relating to data submission are retained and made
available to researchers. Gene Expression Omnibus (GEO)
(4) or ArrayExpress (5) identifiers are used to establish com-
putational links between the literature and any associated
data. If data is publicly available, the system accesses the
repository and downloads the data files. These are then fed
into the relevant analytical pipelines automatically.
Data types and source. The number of breast-related sam-
ples available from BCNTB bioinformatics has increased
from 2574 to 8173. This is attributable to expansions in the
data types available and the resources from which these data
were obtained (Table 1).
Not only has the amount of transcriptomic data in-
creased but users also have access to sequencing, genomic
and mutational data. Originally, all data was obtained from
GEO but BCNTB bioinformatics now incorporates data
from major national and international cancer efforts.
PubMed (enhanced). Adoption of SMAC, development
of novel workflows and optimisation of existing workflows
has allowed for a significant growth in transcriptomic data
(n=5707). The analytical workflow is no longer dependent
on specific annotation dictionaries. Instead, annotations are
extracted from the Investigation Description Format (IDF)
files available from ArrayExpress or the SOFT formatted
family file(s) available from GEO. In addition, the data val-
ues are also downloaded as Series Matrix File(s) and in-
corporated into the relevant analytical workflows. As such,
data generated from a range of platforms is available. By au-
tomating this process, we allow for a faster turnaround time
for data identification, acquisition, preparation and anal-
ysis. We appreciate that a common barrier when attempt-
ing to access data programmatically is inconsistencies in
the manner in which data is reported. Implementing au-
tomated processes often leads to a sacrifice of data qual-
ity for data quantity. To address this issue, all records up-
loaded to BCNTB:Analytics will also be manually curated
by the tissue bank team. So, while datasets will be made
available to the breast cancer research community from the
moment they are analysed, datasets that have been reviewed
are denoted by a blue star. We encourage researchers to
upload their own data to the portal (http://bioinformatics.
breastcancertissuebank.org/upload.jsp) and are preparing
data standards to facilitate this process.
The Cancer Genome Atlas (novel). The Cancer Genome
Atlas (TCGA) (6) was developed to characterise the spec-
trum of genetic alterations associated with malignant trans-
formation, including changes to the DNA sequence, copy
number alterations, chromosomal aberrations and epige-
netic modifications. Over 2.5 petabytes of genomic data,
covering 33 different tumour types, has been generated.
We aim to access and download breast cancer-specific data
available from the TCGA and allow researchers to anal-
yse these. Currently, expression (n=1205) and mutation
(n=1097) data generated using RNA-seq is available for
analysis alongside data from the BCNTB. Genomic and
methylation data will become available in the next release.
Cancer Cell Line Encyclopedia (novel). The Cancer Cell
Line Encyclopedia (CCLE) (7) is a compilation of data
generated from human cancer cell lines. Breast cancer data
generated using RNA-seq, expression (n=56) and mutation
(n=54), and genomic data (Affymetrix Genome-Wide Hu-
man SNP 6.0 array, n=54) has been isolated from the CCLE
and is available for analysis.
BCN tissue bank (novel). A data return policy has been
implemented by the BCNTB. This specifies that data gener-
ated using BCNTB tissues must be returned to the Bank
and made available to future researchers. BCNTB bioin-
formatics will host the returned data, publication data and
sample characteristics, and make it available for analysis.
As the molecular and clinical data for each patient/sample
continues to increase, there will be the opportunity to con-
duct integrative analyses, allowing for a multidimensional
understanding of the samples, their alterations and the
relationships underlying them. Researchers will also have
the opportunity to specify samples of interest and request
matched or similar specimens.
Analytical options. The structure of BCNTB:Analytics
has been expanded and adopts a three-tiered analytical ap-
proach: exploratory, investigative and interpretative. In ad-
dition to enhancing analyses available from the previous re-
lease, we also introduce many novel features such as corre-
lation analyses, identification of copy number aberrations,
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Table 1. Overview of the analyses, data types and visualisation options available from BCNTB:Analytics





PCA    Scatterplots plotly (8)
Histogram
Correlation    Heatmap gplots (9), heatmaply
(10), plotly (8)









   Network visNetwork (12)
Data integration  Scatterplots plotly (8)
Boxplots
Enhanced














   Boxplot plotly (8)
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ASSISTANCE Documentation Available online
Short courses Run throughout
the year
Help/feedback Available online
visualisation of mutational profiles, gene network analyses
and an integrative modality in which data generated by dif-
ferent technologies is overlaid (Figure 1). Furthermore, ex-
perimental data returned to the BCNTB will be available for
investigation. Any novel findings resulting from these anal-
yses will be uploaded to the tissue bank and the associated
clinical/molecular information will be updated.
Principal component analysis (new feature; Figure S1).
The inclusion of principal component analyses (PCA) (17)
allows users to conduct exploratory analyses by reducing
the complexity of multivariate data whilst minimising the
loss of information. Data are transformed into a coordi-
nate system and presented as an orthogonal projection. This
allows researchers to visualise the global structure of the
data and identify key ‘components’ of variation. For each
dataset, scatterplots representing the first two and the first
three principal components (PCs) are presented. To provide
a better understanding of the global variability of the data,



































































Figure 1. Growth and expansion of the data and analytical options available from BCNTB:Analytics.
the fraction of total variance attributed to each PC is also
provided.
Tumour purity (enhanced). Cancer samples frequently
contain a small proportion of infiltrating stromal and im-
mune cells that may not only confound the tumour signal
in molecular analyses but may also have a role in tumouri-
genesis and progression. We apply the ESTIMATE algo-
rithm (13) that uses gene expression data to calculate stro-
mal score, immune score and estimate score, and infers tu-
mour purity from these values. To facilitate the understand-
ing of these scores and their implications in inferring tu-
mour purity we now present all the calculated scores in a
single interactive scatterplot and the related values in a dy-
namic table that can be filtered by key word or tumour pu-
rity value.
Molecular classification (enhanced). The analyses under-
lying this module remain unchanged. Each sample is as-
signed to a molecular subtype and a molecular receptor sta-
tus for oestrogen (ER), progesterone (PR) and Her2 is cal-
culated. The results are presented in a more comprehensive
manner than in the previous release, with full annotations
and sample-level information available for download.
Expression plots (enhanced with new features; Figure S2).
The code and data underlying these analyses has been
optimised and expanded. Complementarity between the
automated and manual process implemented by BC-
NTB:Analytics allows for the underlying clinical data to be
more granular. In turn, these manually-curated compara-
tive groups form the basis of the expression plots, allowing
for greater insights to be obtained from the expression pro-
filing process.
Correlation analysis (new feature; Figure S3). The Pear-
son Product Moment Correlation Coefficient (PMCC) is
applied to define the relationship between user-defined
genes. These are presented in a heatmap in which the colour
of the cell represents the correlation coefficient for each
comparison. The calculated correlation coefficient can be
viewed for each pairwise comparison by hovering over the
heatmap.
Survival analysis (enhanced). In addition to the summary
of survival, based on molecular subtype and a univariate
(single gene) model, available from the previous version,
the effect of multiple genes can also be investigated. Re-
searchers can either conduct the analyses on all samples in
a dataset or choose to focus on a subtype(s) of interest. Re-
sults are presented as Kaplan Meier plots. A summary of
survival covariates (P-value and hazard ratio) for five-, ten-
and overall survival are presented in tabular format.
Copy number aberrations (new feature). A landscape of
copy number alterations can be viewed at both a region- and
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a gene-level. An overview of copy number aberrations, spe-
cific to each biological group in the dataset, are presented
as frequency plots. Heatmaps displaying the copy number
status of a region in which user-defined gene(s) reside can
also be generated.
Mutational profiles (new feature; Figure S4). A summary
of the top somatic single nucleotide variants from matched
tumour-normal samples, as called by MuTect2 (18), can be
viewed as a heatmap. Sample information, such as the num-
ber of mutations per sample and clinical features, and gene
level information, such as the types of mutations identified
per gene, are also presented. In addition to filtering results
by top mutations, researchers also have the ability to inves-
tigate the mutational status of genes of interest.
Gene network analysis (new feature; Figure S5). For each
comparative group defined in the dataset, the interactions
between genes of interest and their primary neighbours
can be displayed in an interactive network. This new fea-
ture takes advantage of the mentha interactome browser
(19), which collects manually-curated interactions from
databases that have adhered to the IMEx consortium (20).
In these gene networks, nodes represent the genes while
edges represent the interactions. Nodes are coloured ac-
cording to the expression level (z-score) in the dataset of in-
terest. A detailed report of the interactions composing the
network, together with the list of PMIDs that support each
relationship, is provided in tabular format.
Integration of multidimensional data (new feature). Pro-
viding researchers with the means to overlay layers of
molecular information to gain a multidimensional view of
the data allows for the identification of alterations that co-
exist within a sample and helps provide greater insight into
the relationships between them.
Data are processed using a standardised workflow to
ensure comparability, reusability and interoperability both
across different datasets and different data types. This en-
sures compatibility between a dataset(s) in which the same
specimen has been analysed using different approaches, al-
lowing for the merging of data obtained from different tech-
nologies. This analytical module allows researchers to in-
tegrate and visualise discrete genetic events, such as DNA
copy-number alterations (CNAs) and mutations, or relative
linear copy-number values with continuous mRNA abun-
dance data for user-defined gene(s). For example, overex-
pression of a group of genes could indicate synergy between
these genes or could be attributable to copy number alter-
ations.
Data return and data sharing. BCNTB bioinformatics has
been designed to allow data sharing, discoverability and
re-usability. This platform is not a bioinformatics silo but
rather a niche within the BCN tissue banking ecosystem
that offers an unparalleled opportunity to add informative
layers of molecular data to existing patient data available
from the Bank.
From the BCN Tissue Bank tab, researchers will be able
to view a summary of all projects using samples from
the BCNTB, along with an indication about publications.
Once molecular data is returned to the Bank and inte-
grated into platform, researchers will be able to analyse
the data (BCNTB:Analytics), query the published findings
(BCNTB:Miner), link to the raw data files, and request
specimens from the BCNTB on matched patients.
Interactive graphics and tables. All results retrieved by the
portal are presented in an interactive format (8). The nature
of these results allows researchers to zoom in/out, focus on
areas of interest, visualise the annotation of data points,
and exclude or include samples in pre-defined biological
groups. Where applicable, information and results are also
presented in tabular format. These are also dynamic, allow-
ing samples to be filtered by features of interest. All figures
can be downloaded as static files of publishing quality.
For each dataset, the molecular results from which the
figures are generated, such as those from the molecular sub-
typing of samples and tumour purity estimates, are pre-
sented in an interactive table. This allows for results to be
inspected at a sample level. These results can be copied or
downloaded in the most common formats (excel spread-
sheet, csv or pdf) for subsequent analyses.
BCNTB: Miner
Restructuring of the data-mining architecture. BC-
NTB:Miner has migrated to a more powerful server,
improving response time to queries. During this time,
two major restructuring processes were completed––the
core architecture of the database was revised and the
annotation/mappings systems were updated. The restruc-
tured data-mining modality encompasses a user-friendly
interface with a clean design that emphasises the querying
parameters available.
Query building and annotation categories. The data man-
agement system underlying the data-mining module was
updated to BioMart 0.9 (21). This has allowed for informa-
tion from the Study Dataset and Gene Dataset, available in
the previous release, to be merged and integrated with En-
sembl features, such as genes, transcripts, proteins, SNPs,
genomic features, gene ontologies, multi-species compar-
isons, and variant source.
The request-response architecture remains the same.
However, the novel environment offered by BioMart 0.9,
in conjunction with the MartWizard GUI adopted by BC-
NTB:Miner, allows for the querying process to be more in-
stinctual than ever before. This interface guides the user
through a query in a logical manner and presents all the pa-
rameters selected in an additive manner on the right-hand
side of the page. The simplification of the interface is ac-
companied by optimisation in the structure of the under-
lying MySQL tables. Moreover, updating the annotations
and mappings from Ensembl 69 to Ensembl 84 ensures that
results retrieved are mapped using up-to-date annotations.
All of these changes help ensure that researchers continue
to experience improvements in the querying process without
having to compromise on the complexity or granularity of
the query. BCNTB:Miner provides users with an intuitive
interface to build custom queries against all the genomics,
methylomics, transcriptomics, proteomics and microRNA
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data that has been mined from the literature and linking to
pathways and mechanisms involved in breast cancer.
DOCUMENTATION AND AVAILABILITY OF THE PLAT-
FORM
A comprehensive user guide is available from the home-
page. The tissue bank bioinformatics team are also avail-
able to answer any additional queries at bioinformat-
ics.breastcancertissuebank@qmul.ac.uk. Furthermore, we
host BCN-funded ‘breast cancer bioinformatics’ courses in
which BCNTB bioinformatics is showcased and explored in
depth.
BCNTB bioinformatics was, and continues to be, de-
signed and developed for researchers. As such, we welcome
any feedback, suggestions or ideas regarding how to im-
prove our resources. An expandable Feedback tab is avail-
able for this purpose.
BCNTB bioinformatics is freely available and has been
tested using Google Chrome, Mozilla Firefox and Safari on
Mac OS X10.12.4 and Windows OS.
LOOKING TO THE FUTURE
The unique relationship between BCNTB bioinformatics
and the Tissue Bank has phenomenal potential in ensuring
that breast cancer data is exploited to its maximal poten-
tial. Not only will we integrate and update specimen/patient
data that is returned to the BCNTB but researchers will
also be able to analyse and integrate their own data into
the portal. To help facilitate this process, we are preparing
data standards for data generated on different platforms.
The standardisation of the data content and structure, in
conjunction with a manual assurance stage, will ensure that
data can be uploaded, analysed and interpreted with ease.
In addition to increasing the amount of data avail-
able to researchers and including data from other
national/international cancer initiatives, such as the
International Cancer Genome Consortium (ICGC), fu-
ture expansions of BCNTB bioinformatics will provide
researchers with the ability to apply predictive models to
the BCNTB returned data. By having access to a rich col-
lection of clinical data and creating virtual patient models,
individual tumours could be characterised at the molecular
level, making it possible to develop prognostic signatures
and identify the potential responses to treatment/drug
repurposing.
It is vital that BCNTB bioinformatics continues to evolve
alongside its in vivo and in vitro components. In future, we
hope that the BCNTB and the BCNTB bioinformatics will
no longer be viewed as separate entities but as niches within
a biobanking research ecosystem, one in which patient ben-
efit is core.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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